Demethylzeylasteral

Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation ^[1][2].
In Vitro:Demethylzeylasteral (0-50 μM, 72 h) inhibits cell growth and proliferation by inducing cell cycle arrest in glioma cells^[1].
Demethylzeylasteral (5, 10 μM, 48 h) inhibits matrix degradation, migration and invasion of breast cancer cells^[2].
Demethylzeylasteral (1-20 μM, 48 h) inhibits cell proliferation and induces apoptosis by inhibiting MCL1 in melanoma cells^[3].
Demethylzeylasteral (0-2 μM, 48 h) inhibits the proliferation, migration, and activation of hepatic stellate cells^[6].
In Vivo:Demethylzeylasteral (30 mg/kg, 6 times every 2 days, i.p.) inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis^[1].
Demethylzeylasteral (4 mg/kg, 5 weeks, i.p.) inhibits the invasion of triple negative breast cancer by blocking classical and non classical TGF - β signaling pathways^[2].
Demethylzeylasteral (30-120 mg/kg, 8 weeks, i.p.) improves inflammation in a unilateral ureteral obstruction rat model by inhibiting the activation of the NF - κ B pathway^[4].
Demethylzeylasteral (10, 40 mg/kg, 30 days, i.g.) can alleviate atherosclerosis in AS rabbits^[5].
Demethylzeylasteral (10, 20 mg/kg, 4 weeks, p.o.) improves CCl4 induced liver fibrosis in mice by inhibiting AGAP2 mediated FAK/AKT signaling^[6].